SOCIODEMOGRAPHIC CHARACTERISTICS OF SARS-COV-2 SEROSURVEILLANCE

STUDIES WITH DIVERSE RECRUITMENT STRATEGIES, CANADA, 2020 TO 2023

Matthew J. Knight[1], Yuan Yu[1], Jiacheng Chen[1], Sheila F. O'Brien[2,3], David L. Buckeridge[1,4],
Carmen Charlton[5,6], W. Alton Russell[1,4]

1. Department of Epidemiology, Biostatistics and Occupational Health, School of Population and
Global Health, McGill University, Montreal, Canada

2. Canadian Blood Services, Ottawa, Canada

3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada

4. COVID-19 Immunity Task Force, Montreal, Canada

5. Canadian Blood Services, Edmonton, Canada

6. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

Corresponding author: Matthew J. Knight (matthew.knight@mail.mcgill.ca), +1-613-854-9571
Suite 1200, McGill College Avenue, Montreal, QC, Canada H3A 1G1

Keywords: Representativeness; Surveillance; COVID-19

ABSTRACT

Background. Serological testing was a key component of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) surveillance. Social distancing interventions, resource limitations, and the need for timely data led to serosurveillance studies using a range of recruitment strategies, which likely influenced study representativeness. Characterizing representativeness in surveillance is crucial to identify gaps in sampling coverage and to assess health inequities.

Methods. We retrospectively analyzed three pre-existing longitudinal cohorts, two convenience samples using residual blood, and one de novo probabilistic survey conducted in Canada between April 2020 – November 2023. We calculated study specimen counts by age, sex, urbanicity, race/ethnicity, and neighborhood deprivation quintiles. We derived a 'representation ratio' as a simple metric to assess generalizability to a target population and various sociodemographic strata.

Results. The six studies included 1,321,675 specimens. When stratifying by age group and sex, 65% of racialized minority subgroups were moderately underrepresented (representation ratio < 0.75). Representation was generally higher for older Canadians, urban neighborhoods, and neighborhoods with low material deprivation. Rural representation was highest in a study that used outpatient laboratory blood specimens. Racialized minority representation was highest in a de novo probabilistic survey cohort.

Conclusion. While no study had adequate representation of all subgroups, less traditional recruitment strategies were more representative of some population dimensions. Understanding demographic representativeness and barriers to recruitment are important considerations when designing population health surveillance studies.

INTRODUCTION

Serological surveillance is a critical input to infectious disease control, including pandemic preparedness and response. In 2020, Canada launched the largest serological surveillance program in its history to monitor population immunity to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), informing COVID-19 epidemiology and antibody dynamics. Between April 2020 and February 2021, many studies began testing blood specimens for SARS-CoV-2 antibodies [1–6]. Challenged by social distancing measures, studies used diverse strategies to recruit participants or obtain blood samples. Recruitment strategy influences study population's characteristics and the extent to which participants represent the general population [7].

Serosurveillance studies can be broadly categorized as convenience samples, de novo probabilistic surveys, or pre-existing longitudinal cohorts. For SARS-CoV-2 serosurveillance, many countries used convenience samples of residual blood specimens due to low operational costs and ease of continued sample collection over time [1,2,8,9]. Convenience samples may introduce selection bias if certain subpopulations are excluded or poorly represented [1,8]. Probabilistic serosurveys, also deployed in many regions to monitor SARS-CoV-2, can mitigate selection biases by using stratified, weight-based approaches to recruitment. De novo designs allow tailoring recruitment to study objectives [4,5,10–12]. However, probabilistic designs are time- and resource-intensive and are sometimes limited by low response rates [6,13]. Sampling within pre-existing longitudinal cohorts can improve efficiency by leveraging an established sampling frame and study infrastructure. But this precludes tailoring the sampling frame to the current research question, and generalizability may be limited by inclusion criteria or attrition.

In this study, we introduce a simple metric for diagnosing the representativeness of subgroups

within a study population. Using this metric, we evaluated the sociodemographic

representativeness of six SARS-CoV-2 serosurveillance studies with diverse recruitment

strategies by age, sex, race/ethnicity, urbanicity, and neighborhood measures of socioeconomic

deprivation. Our findings can inform serosurveillance study design for diverse pathogens.

METHODS

Data

We assessed representativeness by analyzing demographic data from six Canadian study

populations (Table 1). Here, we define a study to be representative if the sociodemographic

composition of the study population matched the census-based target population; we make no

assumptions of the sampling mechanism or inferential validity. This similarity suggests the

interpretation of an effect measure may be generalizable to the target population, but does not

assume the effect estimate, within an uncertainty interval, will be identical between the study and

target populations [14]. The six studies included one de novo cross-sectional probabilistic sample

(the Canadian COVID-19 Antibody and Health Survey 1 [CCAHS-1]), one open longitudinal

cohort recruited from a marketing research panel (Action to Beat Coronavirus study [Ab-C]),

two pre-existing closed longitudinal cohorts (the Canadian Longitudinal Study on Aging

COVID-19 Antibody Study [CLSA], the Canadian Partnership for Tomorrow's Health COVID-

19 Antibody Study [CanPath]), and two serial cross-sectional convenience samples that used

residual blood from blood donations (Canadian Blood Services [CBS]) and specimens collected

for outpatient laboratory testing (Alberta Precision Laboratories [APL]). The included studies

tested specimens collected from April 2020 to November 2023 with sample sizes ranging from

11,050 (CCAHS-1) to 1,039,298 (CBS). Inclusion criteria and enrollment procedures have been

described previously [1,2,6,12,15,16]. This study was reported using the STrengthening the

Reporting of OBservational studies in Epidemiology checklist for cross-sectional studies [17].

114   **Table 1**: Summary of SARS-CoV-2 serological study designs included in the study.

Study	Design	Age	Region	Specimen type	Study time and size	De novo recruitment
Action to Beat Coronavirus (Ab-C)	Pre-existing longitudinal open research cohort	≥ 18	AB, BC, MB, NB, NL, NS, ON, PE, QC, SK, YT[a]	Dried blood spot	25,110 specimens from 10,621 participants May 2020 - April 2022	No
Alberta Precision Laboratories (APL)	Serial cross-sectional convenience sample	≥ 0	AB	Heparinized plasma Plasma Serum	210,905 specimens from 187,887 participants April 2020 - October 2022	No
Canadian Blood Services (CBS)	Serial cross-sectional random sample	≥ 18	AB, BC, MB, NB, NL, NS, ON, PE, SK	Serum	1,035,580 specimens from 446,187 participants May 2020 - November 2023	No
Canadian Covid-19 Antibody and Health Survey 1 (CCAHS-1)	Prospective cross-sectional cohort with direct (ages 1-24) or multi-stage (ages ≥ 25) sampling	≥ 1	AB, BC, MB, NB, NL, NT, NS, NU, ON, PE, QC, SK, YT	Dried blood spot	11,050 specimens from 11,050 participants November 2020 - April 2021	Yes
Canadian Longitudinal Study on Aging (CLSA)[b]	Pre-existing longitudinal closed research cohort	≥ 51	AB, BC, MB, NB, NL, NS, ON, PE, QC, SK	Dried blood spot Plasma	17,310 specimens from 17,310 participants October 2020 - August 2021	No
Canadian Partnership for Tomorrow's Health (CanPath)[c]	Pre-existing longitudinal closed research cohort	≥ 25	AB, BC, MB, NB, NL, NS, ON, PE, QC	Dried blood spot	21,720 specimens from 21,717 participants February 2021 - November 2021	No

Notes: [a]Four specimens were collected from Yukon territory and were excluded from all analyses. [b]Composed of
comprehensive sub-cohort and tracking sub-cohort that recruited participants from seven and 10 provinces,
respectively. [c]Composed of six distinct regional cohorts. AB: Alberta; BC: British Columbia; MB: Manitoba; NB:
New Brunswick; NL: Newfoundland and Labrador; NT: Northwest Territories; NS: Nova Scotia; NU: Nunavut;
ON: Ontario; PE: Prince Edward Island; QC: Quebec; SK: Saskatchewan; YT: Yukon.

From each dataset, we extracted participants' age, sex, postal code, date of specimen collection,

and self-reported race/ethnicity. We used the postal code to classify participants' residence as

urban or rural and to assign participants' neighborhood to a quintile of the Pampalon material

and social deprivation indices [18]. Material deprivation is a composite measure of education,

employment, and income reflecting access to essential material resources. Social deprivation is a

composite measure of living alone, single-parent families, and people who are either separated,

divorced, and/or widowed, reflecting the fragility of social networks. Both measures are derived

from the 2016 Canadian census [19]. We used the date of specimen collection as the sample date

when available (CBS, APL); otherwise, we used the date of questionnaire completion (CanPath,

CCAHS-1, CLSA) or specimen receipt (Ab-C).

Race/ethnicity information was unavailable for the APL study. Deprivation indices were

available for the CBS, APL, CCAHS-1, and CLSA studies. Specimen counts for the CCAHS-1

study were rounded to base 2000 in accordance with data usage guidelines. Age was calculated

as the age at specimen collection (Ab-C, APL, CBS) or questionnaire completion (CanPath,

CLSA, CCAHS-1) and categorized as 0-17 years, 18-26 years, 27-36 years, 37-46 years, 47-56

years, or 57 years and older. For Ab-C specimens collected between December 2020 – April

2021 and July 2021 – September 2021, we used the 2019 baseline age since the age at current

collection could not be calculated. We categorized sex as male or female and excluded

participants who provided alternative responses (n = 138 [Ab-C]) from analyses involving

participant sex. Because race/ethnicity data collection varied between studies and differed from

census categorization, we re-classified participants as 'white' and 'racialized minority' and did

not analyze specific racialized minority groups (Supplementary Tables S1-S2). For studies

allowing multiple encounters with participants, we imputed missing variables when available for

another encounter (CBS, Ab-C, CLSA). We classified participants who identified as both white

and a racialized minority as a racialized minority, and we considered Indigenous identities as a

racialized minority but conducted sensitivity analyses with different classifications. Because only

CCAHS-1 collected specimens from the capital cities of the Canadian territories, we restricted

our primary analysis to specimens collected from Canadian provinces but assessed territorial

representativeness for CCAHS-1 separately. We excluded participants who did not meet the

inclusion criteria of their respective study and who were missing age, province/territory of

residence, or serology test result data. For the CBS study, we did not assess the

representativeness of the 0-17-year-old age group because there were no donors younger than 17.

We calculated specimen counts using complete cases within each set of demographic strata (e.g.,

participants missing race/ethnicity were excluded when stratifying by age, sex, and race/ethnicity

but not when stratifying by age, sex, and urbanicity).

Representation ratio analysis

To assess the representativeness of subgroups defined by one or more sociodemographic

variable, we derived a *representation ratio* by dividing the proportion of study specimens in a

sociodemographic subgroup by the proportion of participants in the subgroup from a target

population. A representation ratio less than one indicates the group is underrepresented relative

to the target population, and a ratio greater than one indicates overrepresentation. We defined the

target subgroup distribution using weighted 2016 Canadian census counts [19], restricting by age

and province/territory to match studies' inclusion criteria (Table 1) and rounded to the nearest

multiple of zero or five. We calculated representation ratios on unweighted study populations to

assess the unadjusted sociodemographic composition of each study except for CCAHS-1, due to

guidelines restricting unweighted analyses [6]. For the target distributions, race/ethnicity counts

were derived using the census population group variable and Indigenous-identifying respondents

were classified as racialized minorities [19]. Indigenous-identifying census respondents were

classified as racialized minorities, but were excluded when generating ratios for CLSA and

CanPath since Indigenous status was unavailable for most participants. We assessed the impact

of excluding Indigenous-identifying census respondents in a second sensitivity analysis. We

performed bootstrapping (n = 5000) to generate an uncertainty distribution for each

representation ratio.

Sample count by strata analysis

In some cases, statistical adjustment or subsampling may allow derivation of representative

population statistics from large, unbalanced study populations if there are sufficient samples

from less represented strata [20]. To inform whether this would be feasible in our study

populations, we assessed the number of strata with counts greater than 25 when grouped by age,

sex, province of residence, urbanicity, race/ethnicity, and date of specimen collection binned into

two-month intervals. All analyses were conducted in R version 4.3.1 [21].

RESULTS

Study population

During data pre-processing, we excluded 3,718 observations for CBS (0.4%), 3,871 for APL

(1.8%), 2,052 for Ab-C (7.6%), 2,024 for CLSA (10.5%), and 4,258 for CanPath (16.4%) due to

missing data or failure to meet inclusion criteria. We analyzed the remaining 1,035,580 (CBS),

210,905 (APL), 25,110 (Ab-C), 21,720 (CanPath), 17,310 (CLSA), and 11,050 (CCAHS-1)

observations (Supplementary Table S3). For Ab-C, CLSA, and CanPath, the minimum age of

participants included in our analysis (Table 1) was older than the minimum age specified in their

inclusion criteria [12,15,16]. Across studies, the largest number of observations were in the 57

and older age group (34.4% [CCAHS-1] – 91.4% [CLSA]). Observations for the 18-26-year-old

age group were generally low (0.0% [CanPath] – 5.6% [APL]) but were higher for CBS (10.6%)

and CCAHS-1 (11.8%). Among studies for which neighborhood deprivation was available,

specimen counts across social deprivation quintile were balanced, but only 8.2% (CBS), 8.4%

(APL), 9.6% (CLSA), and 13.1% (CCAHS-1) of specimens were provided from the most

materially deprived quintile of neighborhoods. Most studies skewed white (78.2% [Ab-C] –

94.7% [CLSA]) and female (52.3% [CLSA] – 65.6% [CanPath]), except CBS which skewed

white (81.7%) and male (58.2%). Rural specimens accounted for 8.6% (CanPath) – 17.6%

(CCAHS-1) of all specimens across studies. Convenience samples collected substantially more

specimens for each demographic strata compared to other recruitment strategies (Supplementary

Figures S1-S4).

Representation ratio analysis

Studies had reasonable representation across sexes (representation ratio 0.7-1.3; Figure 1) and,

when available, by social deprivation (Supplementary Figure S5). In all studies, racialized

minority subgroups were underrepresented (representation ratio < 1) for some age and sex strata

(Figure 2). Racialized minority representation, while still low, was often better in older age

groups (Ab-C, CanPath, and CLSA), but was better for younger age groups among women for

CBS. Urban regions produced larger representation ratios by age and sex strata than rural regions

in all studies (Figures 1-2). While APL had reasonable representation of all material deprivation

quintiles and rural residents (representation ratio 0.8-1.3), the CBS population skewed towards

less materially deprived neighborhoods and urban regions (though rural representation for CBS

was higher than the three longitudinal cohort studies). 18-26-year-old males were

underrepresented across most sex and urbanicity strata in all studies for which they were eligible

to be sampled.

Figure 1: SARS-CoV-2 serological study representativeness by sex, urbanicity, and racial/ethnic identity. Representativeness was calculated by dividing the proportion of study specimens collected from a subgroup by the proportion of general population in the subgroup. Total population counts were estimated using the 2016 Canadian census [19]. Bolded representation ratios indicate greater than 95% of subgroup bootstrap replicates produced representation ratios below 0.75. Bootstrapping was not performed for studies with weighted representation ratios (CCAHS-1).

Figure 2: SARS-CoV-2 serological study representativeness by age group, sex, urbanicity,

racial/ethnic identity, and material deprivation quintile. Representativeness was calculated

by dividing the proportion of study specimens collected from a subgroup by the proportion of

general population in the subgroup. Total population counts were estimated using the 2016

Canadian census [19]. Material deprivation scores were not available for Ab-C and CanPath

studies. Bolded representation ratios indicate greater than 95% of subgroup bootstrap replicates

produced representation ratios below 0.75. Bootstrapping was not performed for studies with

weighted counts (CCAHS-1).

Among 18-46-year-olds, specimens from the Ab-C open cohort produced larger representation

ratios across sex and urbanicity strata compared to CanPath (Figure 2). Representation ratios of

18-46-year-old rural residents were generally larger across age and sex strata in CCAHS-1 than

several studies with probabilistic recruitment strategies (Ab-C, CanPath). Racialized minorities

aged 47 years and older were sufficiently represented (representation ratio 0.8-1.3) in the Ab-C

open cohort but were underrepresented in the CanPath and CLSA closed cohorts, except for

males aged 57 and older in CanPath. Of the two convenience samples, the CBS study was more

representative of participants aged 18-46 across sex and urbanicity strata, whereas the APL study

was more representative of individuals aged 47 and older. In CCAHS-1, the only study that

sampled in the three Canadian territories, 0-17-year-olds were underrepresented across sexes in

territorial specimens (Supplementary Figure S6). Bootstrapping revealed low uncertainty in

whether a representation ratio was greater or less than one for most subgroups (Supplementary

Figures S7-S13). A sensitivity analysis reclassifying mixed race/ethnicity participants as white

had little impact except for the Ab-C cohort, for which 55% of racialized minorities were

reclassified as white, leading to lower representation ratios (Supplementary Figures S14-S15).

Including Indigenous-identifying individuals as racialized minorities in the representation ratio

denominator for studies for which data were unavailable (CLSA and CanPath) had little impact

on findings (Supplementary Figure S16).

Sample count analysis

The convenience samples with large overall sample size produced substantially more cells with

counts greater than 25 across 4 levels of stratification compared to all other study designs in the

primary analysis (Table 2) and sensitivity analysis (Supplementary Table S4). Pre-existing

closed probabilistic cohorts (CLSA, CanPath) produced a greater proportion of cells with counts

greater than 25 than other probabilistic recruitment strategies (Ab-C, CCAHS-1) for all strata.

307   **Table 2**: Percentage of SARS-CoV-2 serology study demographic subgroups with greater than

308   25 collected specimens.

Study (specimen count)	Months sampled	Demographic subgroups			
		Age, Sex, Province, Month	Age, Sex, Province, Urban, Month	Age, Sex, Province, Race/Ethnicity, Month	Age, Sex, Province, Race/Ethnicity, Urban, Month
CBS blood donor (1,035,580)	41	92%	74%	70%	52%
APL outpatient laboratory (210,905)	27	94%	84%	NA	NA
Ab-C open cohort (25,110)	18	31%	20%	20%	12%
CanPath closed cohort (21,720)	10	40%	31%	32%	26%
CLSA closed cohort (17,310)	11	50%	36%	34%	27%
CCAHS-1 closed cohort (11,050)	6	33%	20%	21%	13%

309   *Notes:* Date of sample collection was binned into 2-month intervals for each level of stratification. All
310   specimen counts were unweighted.

DISCUSSION

In this study, we developed a simple method for characterizing study population

representativeness and applied it to describe the variability in sociodemographic

representativeness across six SARS-CoV-2 serosurveillance studies with diverse recruitment

strategies. No study was adequately representative of all sociodemographic subgroups.

Representation ratios are a flexible diagnostic measure for characterizing study populations.

Ratios can consider any combination of characteristics for which reliable estimates of their

distribution in a target population are available. Ratios can be used to compare study populations,

even when target populations differ, and can be estimated before and after application of sample

weights. Notably, representation ratios do not provide insights into the relationship between

participant characteristics and a study's estimand, and do not address unmeasured confounding

within subgroups.

Probabilistic surveys have traditionally been considered the 'gold standard' for obtaining

representative samples [7]. Use of administrative datasets to construct sampling frames often

provides superior population coverage compared to non-probability samples that rely on

participant self-selection. The statistical framework also permits estimation of sampling errors

and characteristics associated with non-response [22]. While resource constraints may limit the

ability of probabilistic designs to perform repeated specimen collection, non-probability

sampling within continuous streams of residual blood specimens, such as blood donors, may be

more feasible for modelling longitudinal trends, which can also incorporate complex geographic

structures [23]. The generalizability of probabilistic designs may also be limited if differences

between respondents and non-respondents are non-random [7]. Bias may be introduced via a

'healthy volunteer' effect whereby cohort participants are healthier than the general population

[24], similar to the 'healthy donor' bias documented in blood donor research cohorts [25]. Where

available, response rates of the included studies were fairly low (23% [CCAHS-1], 25% [Ab-C]

[6,12]; these response rates exclude individuals who completed a questionnaire but did not

provide a blood sample). This suggests non-response bias could partially explain some of the

observed differences in representativeness between study designs. The above response rates are

consistent with other probabilistic serosurveys [11], although response rates as high as 69% have

been reported [10].

Many large-scale SARS-CoV-2 studies relied on blood donor and healthcare patient populations

for serology specimens [22,26]. Blood donors have been discounted as a population for public

health surveillance, while the potential for expanded screening of residual outpatient laboratory

samples remains unclear. However, we found the representativeness of these convenience

populations compared favorably to other designs for some sociodemographic dimensions. For

low- and middle-income countries with limited operational resources, leveraging residual blood

samples may provide a cost-effective avenue to obtain representative data. Future studies should

evaluate the potential of linkage to administrative datasets to better characterize

representativeness and derive statistical weights for adjustment. Gaps in demographic

representation may be overcome by synthesizing data from multiple surveillance streams, though

differences in choice of assay, use of venous blood draws or dried blood samples, and the format

or availability of variables can curtail the ability to synthesize data across studies [27,28].

Racialized minorities were underrepresented across all studies. Language barriers and skepticism

of research or medical institutions may contribute to poor representation of some minority

groups [29,30]. While use of stratified random sampling or sampling weights may improve

sample representativeness, they do not address the underlying individual and societal factors

governing participation in health research. Direct engagement and collaboration with community

members throughout the research cycle may mitigate recruitment barriers by facilitating trust,

reducing misinformation, and ensuring study materials are accessible [30,31]. Racialized

minorities may be better represented in healthcare cohorts like APL [32], though a lack of race-

based data in Canadian administrative healthcare datasets may make this difficult to measure

[33]. Notably, representation of racialized minorities improved as age increased in most studies

requiring participant opt-in (Ab-C, CLSA, CanPath), but young minorities exhibited better

representativeness compared to older subgroups in CBS. Lack of a standardized definition of

participant race/ethnicity impeded comparison across studies and prevented assessment of

representativeness by specific minority group.

Several other dimensions of representativeness varied across studies. The Ab-C open cohort was

substantially more representative of 18-46-year-olds across sex and urbanicity strata compared to

the CanPath longitudinal closed cohort (Figure 2). CLSA and CanPath recruited participants

aged 45-85 in 2010 and 35-74 in 2009, respectively, leading to older age distributions for their

COVID-19 sub-studies [15,16]. Between convenience samples, individuals residing in highly

materially deprived areas were underrepresented when using blood donations (representation

ratio 0.4–0.6), but not when using outpatient labs (representation ratio 0.9-1.2). Donor eligibility

criteria, along with the 'healthy donor effect' or other unmeasured socioeconomic factors, may

homogenize the demographic composition of the sampled donor pool [25]. Rural regions were

consistently underrepresented compared to urban counterparts in all studies, which may be due to

urban-centric recruitment patterns or willingness to travel for specimen collection (Figures 1-2).

The study had several limitations. First, our analysis considered representativeness by age, sex,

race/ethnicity, urbanicity, and neighborhood deprivation. Many other sociodemographic

dimensions are important considerations for representativeness in serosurveillance studies,

particularly those related to health and disability. We hypothesize a 'healthy participant'

sampling bias may have led to underrepresentation of individuals with poor health and/or

disability in all study populations except outpatient laboratories [24,25]. Prior analyses of the

pre-existing longitudinal cohorts included in our study indicated participants are more educated

and/or have higher income than the general population [12,15,16], as are blood donors in the

United States [34]. Second, the measurement of race/ethnicity differed between studies.

Race/ethnicity options for CBS included four mutually exclusive categories, while the Ab-C,

CCAHS-1, CanPath, CLSA, and census datasets permitted selection of multiple racial/ethnic

identities. This necessitated dichotomizing the race/ethnicity variable as white or racialized

minority and may have biased the CBS representation estimate if individuals who identified as

mixed race/ethnicity selected their race/ethnicity as white during donation. Additionally, due to

unavailable Indigenous identity data, we modified our representation assessment for the CLSA

and CanPath studies by omitting Indigenous-identifying individuals from the census dataset. Our

sensitivity analysis suggests this did not substantially impact our findings (Supplementary Figure

S16). Third, we restricted our analysis to SARS-CoV-2 serostudies conducted within a single

country and used an acceptability level of underrepresentation that is context-specific and open

to interpretation. We focused on strata with fewer than 25 samples in our cell count analysis, but

this threshold was largely arbitrary. Fourth, we did not analyze factors shaping the

sociodemographic composition of each study, including intentional oversampling. For example,

CCAHS-1 used a stratified random sampling strategy that oversampled geographic regions with

greater COVID-19 prevalence and less populated regions to improve estimate precision. Less

populated areas of Canada often have fewer racialized minorities, which likely contributes to

lower representation ratios [6]. Understanding the causes and consequences of each study's

sociodemographic composition requires more detailed analysis than is presented here. Finally,

our study is not a comprehensive assessment of all SARS-CoV-2 serology studies conducted in

Canada. Demographic groups excluded here were evaluated elsewhere [35].

Understanding variability in demographic representation between study designs is an important

consideration when planning serosurveillance studies, which increasingly leverage pre-existing

samples or cohorts. This study provides a simple metric to evaluate and compare the

representativeness of study populations. We found that underrepresentation of racialized

minorities and younger age groups was common and not restricted to convenience samples,

which had better representation for some sociodemographic strata. This suggests that

representative estimates could be obtained in resource-constrained settings by leveraging lower-

cost approaches, such as existing blood or laboratory services, compared to large-scale

probabilistically sampled serosurveys. Identifying coverage barriers is vital to support adequate

representation and detection of disease trends within demographic subgroups. We also observed

differences in the measurement of participant race/ethnicity between studies. This highlights the

necessity for consistent, and sufficient, measurement of sociodemographic variables, along with

the need to adopt a standardized approach to the measurement of self-identified race/ethnicity in

Canada.

ABBREVIATIONS

Ab-C   Action to Beat Coronavirus

APL   Alberta Precision Laboratories

CanPath   Canadian Partnership for Tomorrow's Health

CBS   Canadian Blood Services

CCAHS-1   Canadian COVID-19 Antibody and Health Survey 1

CLSA   Canadian Longitudinal Study on Aging

SARS-CoV-2   Severe acute respiratory syndrome coronavirus-2

DECLARATIONS

Ethics approval and consent to participate

All studies analyzed were approved by a Research Ethics Board or Institutional Review Board of

a Canadian institution as reported previously. This secondary analysis of six studies was

approved by the McGill University Faculty of Medicine and Health Sciences Research Ethics

Board (study number 22-03-077).

Consent for participation

Not applicable.

Availability of data and materials

The authors are not authorized to share individual-level data from any study. Processes are

available for researchers to request access to datasets for studies that have undergone

institutional ethical approval. Data from Canadian Blood Services and Alberta Precision

Laboratories may be made available upon request, subject to internal review, privacy legislation,

data sharing agreements, and research ethics approval. The CCAHS-1 study by Statistics Canada

can be analyzed for approved projects at Research Data Centres located across Canada

(https://www.statcan.gc.ca/en/microdata/data-centres/access). Data are available from the

Canadian Longitudinal Study on Aging (www.clsa-elcv.ca) for researchers who meet the criteria

for access to de-identified CLSA data. Access to the Ab-C study data can be requested through

the COVID-19 Immunity Task Force Databank (https://portal.citf.mcgill.ca/). Access to the

CanPath data can be requested through the CanPath data portal (https://portal.canpath.ca/).

Analytical code will be available in a public repository upon publication.

Competing interests

The authors declare that they have no competing interests.

Funding

WAR was supported by funding from Canadian Blood Services and the COVID-19 Immunity

Task Force.

Authors' contributions

MJK and WAR designed the study with input from DLB, SFO, and CC. MJK, YY, and JC

contributed to data analysis. MJK and WAR drafted the initial manuscript. All

authors revised the manuscript and approved the final version.

Acknowledgements

This research was made possible using data collected by Canadian Blood Services' SARS-CoV-

2 Seroprevalence Study; the Canadian Partnership for Tomorrow's Health (CanPath – formerly

CPTP) COVID-19 Antibody study and its regional cohorts the BC Generations Project, Alberta's

Tomorrow Project, the Ontario Health Study, CARTaGENE, Manitoba Tomorrow Project and

the Atlantic Partnership for Tomorrow's Health; the Action to Beat Coronavirus in Canada (Ab-

C) study; the Alberta Precision Laboratories study; the Canadian COVID-19 Antibody and

Health Survey (CCAHS) conducted by Statistics Canada, and the Canadian Longitudinal Study

on Aging (CLSA). We thank the participants, staff, and researchers of all six studies. We also

thank Scott McLeish for the insightful discussions which greatly improved the quality of the

manuscript. Funding for the CLSA is provided by the Government of Canada through the

Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the

Canada Foundation for Innovation, as well as the provinces, Newfoundland, Nova Scotia,

Quebec, Ontario, Manitoba, Alberta, and British Columbia. Funding for support of the CLSA

COVID-19 questionnaire-based study is provided by the Juravinski Research Institute, Faculty of

Health Sciences, McMaster University, the Provost Fund from McMaster University, the

McMaster Institute for Research on Aging, the Public Health Agency of Canada/CIHR grant

reference CMO 174125 and the government of Nova Scotia. This research has been conducted

using the CLSA Baseline Comprehensive Dataset v7.0, Baseline Tracking Dataset v4.0, Follow-

up 1 Comprehensive Dataset v4.0, Follow-up 1 Tracking Dataset v3.0, Follow-up 2

Comprehensive Dataset v1.0, Follow-up 2 Tracking Dataset v1.0, COVID-19 Questionnaire

Study Dataset v1.1, and COVID-19 Seroprevalence Study Dataset v1.0 under Application

Number 2209005. The CLSA is led by Drs. Parminder Raina, Christina Wolfson, and Susan

Kirkland. We appreciate the funding that made each study possible, including the support each

study received from the Government of Canada through the COVID-19 Immunity Task Force.

The opinions expressed in this manuscript are the author's own and do not reflect the views of

the data providers and/or their institutions.

REFERENCES

1. O'Brien SF, Caffrey N, Yi QL, et al. Cross-Canada Variability in Blood Donor SARS-CoV-2 Seroprevalence by Social Determinants of Health. Microbiology Spectrum. 2023;11(1):e03356-22. 10.1128/spectrum.03356-22

2. Charlton CL, Nguyen LT, Bailey A, et al. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic. Microbiology Spectrum. 2021;9(1):e00291-21. 10.1128/Spectrum.00291-21

3. Jha, Prabhat. Action to beat Coronavirus study: Dataset contributed to the CITF Databank. Version DRAFT. Borealis. https://doi.org/doi:10.5683/SP3/LA2IKO

4. Canadian Longitudinal Study on Aging. Data Support Document SARS-CoV-2 Antibodies. 2024.

5. Canadian Partnership for Tomorrow's Health. COVID-19 initiatives. CanPath - Canadian Partnership for Tomorrow's Health. Available from: https://canpath.ca/covid-19-initiatives/.

6. Statistics Canada. Canadian COVID-19 Antibody and Health Survey (CCAHS). 2020. Available from: https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=1287991

7. Cornesse C, Bosnjak M. Is there an association between survey characteristics and representativeness? A meta-analysis. Survey Research Methods. 2018;12(1):1-13. 10.18148/srm/2018.v12i1.7205

8. Offergeld R, Preußel K, Zeiler T, et al. Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in

Germany—Results from the SeBluCo Study 2020–2022. Pathogens. 2023;12(4):551.

10.3390/pathogens12040551

9.   Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-

CoV-2 IgG antibodies, Greece, March and April 2020. Eurosurveillance.

2020;25(31):2001369. 10.2807/1560-7917.ES.2020.25.31.2001369

10.   Pérez-Gómez B, Pastor-Barriuso R, Fernández-de-Larrea N, et al. SARS-CoV-2

Infection During the First and Second Pandemic Waves in Spain: The ENE–COVID Study.

Am J Public Health. 2023;113(5):533-544. 10.2105/AJPH.2023.307233

11.   Ward H, Atchison C, Whitaker M, et al. Design and Implementation of a National

Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-

Testing: The REACT-2 Study. Am J Public Health. 2023;113(11):1201-1209.

10.2105/AJPH.2023.307381

12.   Tang X, Sharma A, Pasic M, et al. Assessment of SARS-CoV-2 Seropositivity During

the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA

Network Open. 2022;5(2):e2146798. 10.1001/jamanetworkopen.2021.46798

13.   Patel EU, Bloch EM, Tobian AAR. Severe Acute Respiratory Syndrome Coronavirus 2

Serosurveillance in Blood Donor Populations. The Journal of Infectious Diseases.

2022;225(1):1-4. 10.1093/infdis/jiab517

14.   Rudolph JE, Zhong Y, Duggal P, et al. Defining representativeness of study samples in

medical and population health research. BMJ Med. 2023;2(1):e000399. 10.1136/bmjmed-

2022-000399

15.   Raina P, Wolfson C, Kirkland S, et al. Cohort Profile: The Canadian Longitudinal Study

on Aging (CLSA). International Journal of Epidemiology. 2019;48(6):1752-1753j.

10.1093/ije/dyz173

16.   Dummer TJB, Awadalla P, Boileau C, et al. The Canadian Partnership for Tomorrow

Project: A pan-Canadian platform for research on chronic disease prevention. CMAJ.

2018;190(23):E710-E717. 10.1503/cmaj.170292

17.   von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of

Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting

observational studies. Epidemiology. 2007;18(6):800-804.

18.   Pampalon R, Hamel D, Gamache P, et al. An area-based material and social deprivation

index for public health in Québec and Canada. Can J Public Health. 2012;103(8 Suppl

2):S17-22. 10.1007/BF03403824

19.   Statistics Canada. Census Profile, 2016 Census. 2017. Available from:

https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E

20.   Downes M, Carlin JB. Multilevel regression and poststratification as a modeling

approach for estimating population quantities in large population health studies: A simulation

study. Biometrical Journal. 2020;62(2):479-491. 10.1002/bimj.201900023

21.   R Core Team. R: A Language and Environment for Statistical Computing. Vienna,

Austria: R Foundation for Statistical Computing; 2023. https://www.R-project.org/.

22.   Lindan CP, Desai M, Boothroyd D, et al. Design of a population-based longitudinal

cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco

Bay Area. Annals of Epidemiology. 2022;67:81-100. 10.1016/j.annepidem.2021.11.001

23.   Yu Y, Knight MJ, Gibson D, et al. Temporal trends in disparities in COVID-19

seropositivity among Canadian blood donors. International Journal of Epidemiology.

2024;53(3):dyae078. 10.1093/ije/dyae078

24.   Froom P, Melamed S, Kristal-Boneh E, et al. Healthy Volunteer Effect in Industrial

Workers. Journal of Clinical Epidemiology. 1999;52(8):731-735. 10.1016/S0895-

4356(99)00070-0

25.   Atsma F, Veldhuizen I, Verbeek A, et al. Healthy donor effect: Its magnitude in health

research among blood donors. Transfusion. 2011;51(8):1820-1828. doi:10.1111/j.1537-

2995.2010.03055.x

26.   Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large

nationwide sample of patients on dialysis in the USA: A cross-sectional study. The Lancet.

2020;396(10259):1335-1344. doi:10.1016/S0140-6736(20)32009-2

27.   Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-

CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay. Journal

of Clinical Virology. 2021;136:104739. 10.1016/j.jcv.2021.104739

28.   Patel EU, Bloch EM, Clarke W, et al. Comparative Performance of Five Commercially

Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals

with High Neutralizing Titers. Journal of Clinical Microbiology.

2021;59(2):10.1128/jcm.02257-20. 10.1128/jcm.02257-20

29.   Etti M, Fofie H, Razai M, et al. Ethnic minority and migrant underrepresentation in

Covid-19 research: Causes and solutions. eClinicalMedicine. 2021;36.

10.1016/j.eclinm.2021.100903

30.   Bonevski B, Randell M, Paul C, et al. Reaching the hard-to-reach: A systematic review of

589   strategies for improving health and medical research with socially disadvantaged groups.

590   BMC Medical Research Methodology. 2014;14(1):42. 10.1186/1471-2288-14-42

591   31.   Ekezie W, Czyznikowska BM, Rohit S, et al. The views of ethnic minority and

592   vulnerable communities towards participation in COVID-19 vaccine trials. Journal of Public

593   Health. 2021;43(2):e258-e260. 10.1093/pubmed/fdaa196

594   32.   Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large

595   nationwide sample of patients on dialysis in the USA: A cross-sectional study. The Lancet.

596   2020;396(10259):1335-1344. 10.1016/S0140-6736(20)32009-2

597   33.   Khan MM, Kobayashi K, Vang ZM, et al. Are visible minorities "invisible" in Canadian

598   health data and research? A scoping review. International Journal of Migration, Health and

599   Social Care. 2017;13(1):126-143. 10.1108/IJMHSC-10-2015-0036

600   34.   Patel EU, Bloch EM, Grabowski MK, et al. Sociodemographic and behavioral

601   characteristics associated with blood donation in the United States: A population-based

602   study. Transfusion. 2019;59(9):2899-2907. 10.1111/trf.15415

603   35.   Atkinson A, Albert A, McClymont E, et al. Canadian SARS-CoV-2 serological survey

604   using antenatal serum samples: A retrospective seroprevalence study. Canadian Medical

605   Association Open Access Journal. 2023;11(2):E305-E313. 10.9778/cmajo.20220045